PHARMACEUTICAL 2021

Alnylam Pharmaceuticals INC
Rank 278 of 394



PHARMACEUTICAL 2021

Alnylam Pharmaceuticals INC
Rank 278 of 394

The relative strengths and weaknesses of Alnylam Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alnylam Pharmaceuticals INC compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 22% points.The greatest weakness of Alnylam Pharmaceuticals INC is the variable Liabilities, reducing the Economic Capital Ratio by 84% points.

The company's Economic Capital Ratio, given in the ranking table, is 185%, being 71% points below the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	2,614,777
Cost of Goods Sold	78,052
Intangible Assets	0
Liabilities, Current	585,270
Liabilities, Non-Current	556,041
Other Assets	327,255
Other Compr. Net Income	-7,104
Other Expenses	2,681
Other Liabilities	1,249,503
Other Net Income	-27,162
Other Revenues	492,853
Property and Equipment	465,029
Research and Development	654,819
Selling, General and Administrative Expense	588,420

Output Variable	Value in 1000 USD
Assets	3,407,061
Liabilities	2,390,814
Expenses	1,323,972
Revenues	492,853
Stockholders Equity	1,016,247
Net Income	-858,281
Comprehensive Net Income	-861,833
BaseVar	3,824,483
ECR before LimitedLiability	47%
Economic Capital Ratio	185%